Moneycontrol PRO
HomeNewsFortishealthcare

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Fortis Healthcare Q1 PAT may dip 58.3% YoY to Rs 109.8 cr: Prabhudas Lilladher

    Fortis Healthcare Q1 PAT may dip 58.3% YoY to Rs 109.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 3 percent Y-o-Y (up 5.4 percent Q-o-Q) to Rs 1,452.3 crore, according to Prabhudas Lilladher.

  • SP Tulsian analysis Fortis Healthcare Q3 results

    SP Tulsian analysis Fortis Healthcare Q3 results

    Fortis Healthcare, the company had a board meet yesterday where it released its Q2 and Q3 results. However, the Auditor- Deloitte, Haskins & Sells LLP said it wasn't able to come to a conclusion on the Financial Statement and has raised some issues in its report as well. Watch the interview of SP Tulsian of SP Tulsian.Com with Prashant Nair and Ekta Batra on CNBC-TV18, in which he shared his readings and outlook on Fortis Healthcare.

  • Analysts remain positive on Fortis Healthcare, expect up to 38% upside in stock price

    Analysts remain positive on Fortis Healthcare, expect up to 38% upside in stock price

    Motilal Oswal is bullish on the stock, saying it is a top pick in healthcare delivery space but slashed target price to Rs 220 (from Rs 240 earlier), expecting relatively slow margin expansion in the medium term.

  • Fortis Q4 PAT seen up 2.4% to Rs 34.7 cr: ICICI Securities

    Fortis Q4 PAT seen up 2.4% to Rs 34.7 cr: ICICI Securities

    Net Sales are expected to increase by 4.3 percent Q-o-Q (up 8.6 percent Y-o-Y) to Rs 1181.9 crore, according to ICICI Securities. Fortis to report net profit at 34.7 crore up 2.4% quarter-on-quarter.

  • Fortis Health expects SRL demerger to be completed in 6 months

    Fortis Health expects SRL demerger to be completed in 6 months

    Fortis Healthcare reported a healthy set of numbers for the third quarter. The firm clocked a revenue growth of over 10 percent compared to the corresponding quarter last fiscal.

  • Fortis Q3 PAT may dip 2.1% to Rs 42.8 cr: ICICI Securities

    Fortis Q3 PAT may dip 2.1% to Rs 42.8 cr: ICICI Securities

    Net Sales are expected to decrease by 1.5 percent Q-o-Q (up 13.1 percent Y-o-Y) to Rs 1177.8 crore, according to ICICI Securities.

  • Demerger of diagnostics business will help unlock value: Fortis

    Demerger of diagnostics business will help unlock value: Fortis

    Fortis Healthcare's board has given an in-principle nod for the demerger of its diagnostics business. The demerger, on which a committee will take a decision on August 19, is an opportunity to unlock value, says CEO Bhavdeep Singh.

  • No new hopitals in near future, will spend on R&D: Fortis CEO

    No new hopitals in near future, will spend on R&D: Fortis CEO

    In an interview with CNBC-TV18, Bhavdeep Singh, CEO of Fortis said that there are no plans to add new hospitals in the near future but the company will spend majorly on medical equipments and technology.

  • Not looking at SRL Diagnostics' IPO: Fortis Healthcare

    Not looking at SRL Diagnostics' IPO: Fortis Healthcare

    Fortis Healthcare Thursday reported a consolidated net profit of Rs 87.28 crore for the first quarter ended June 30, 2015-16, mainly on account of gains from divestment of international businesses.

  • See net debt fall on S'pore assets' sale proceeds: Fortis

    See net debt fall on S'pore assets' sale proceeds: Fortis

    Shivinder Singh, executive vice-chairman, Fortis Healthcare says the company clocked a growth of 12 percent this year in its India business at about Rs 970 crore.

  • Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

  • Fortis Q1 PAT at Rs 14.03cr, prepares for next growth phase

    Fortis Q1 PAT at Rs 14.03cr, prepares for next growth phase

    Fortis Healthcare (India) posted a consolidated net profit of Rs 14.03 crore for the first quarter ended June 30, 2011.

  • Fortis Healthcare expects to set up 900 beds in next 1 year

    Fortis Healthcare expects to set up 900 beds in next 1 year

    Commenting on Fortis Healthcare's performance during the quarter, its managing director Shivinder Mohan Singh said, "We have set up three greenfield hospitals, adding 1,000 beds and expect to set up another 900 beds in the next one year."

  • Fortis Healthcare Q3 PAT seen up 62% at Rs 35 cr

    Fortis Healthcare Q3 PAT seen up 62% at Rs 35 cr

    Hospital chain Fortis Healthcare is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax (PAT) is expected to go up by 62% to Rs 35 crore as against Rs 21.7 crore in same period the previous year and up from Rs 74.8 crore in previous quarter.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347